ARTERIAL HYPERTENSION IN PATIENTS WITH DIABETES MELLITUS: AN INDIVIDUALIZED CHOICE OF ANTIHYPERTENSIVE MEDICATIONS
Abstract
The patients with arterial hypertension (AH) and diabetes mellitus (DM) are at high risk of cardiovascular events. The modern pharmacotherapy potential in patients with AH and DM is reviewed. The evidence base for various antihypertensive classes in cardiovascular event prevention among these patients is analysed.
About the Authors
T. E. Morozova
Первый Московский государственный медицинский университет имени И.М.Сеченова, Москва
Russian Federation
Russian Federation
T. B. Andrushchishina
Первый Московский государственный медицинский университет имени И.М.Сеченова, Москва
Russian Federation
Russian Federation
References
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом Под редакцией И.И. Дедова, М.В. Шестаковой (2-е издание) Москва 2006 г.
2. Мычка В.Б., Сергиенко В.Б., Горностаев В.В и др. Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом // Артериальная гипертензия. Прил. к Consilium Medicum 2003 т. 09; №5.
3. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010.
4. Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом (результаты исследования ALMAZ). Системные гипертензии 2006(8); 2.
5. Brixius K. et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium // British Journal of Pharmacology 2001;133: 1330–1338
6. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial // Lancet 1999; 353: 9-13.
7. Cooper M. The prevalence of hypertension in patients with diabetes. In: Hypertension and diabetes (Ed. Mogensen CE). Lippincott Williams & Wilkins, London, 2003, 3–9.
8. Haasis R, Bethge H Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of trearment with bisoprolol and metoprolol: a randomized multicentre double–blind study (BISOMET) // Eur Heart J 1987; 8: 103–113.
9. Haffner M., Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction // N. Engl. J. Med., 1999, 339, 229–234.
10. Heinemann I., Heise T., Ampudia J. et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity // Europ. Heart J. 1995; 25: 595–600.
11. Hunt KJ, Resendez RG, Williams K et al. San Antonio Heart StudyNational Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study // Circulation. 2004 Sep 7;110(10):1251-7.
12. Janka H.U., Ziegler A.G., Disselhoff G. et al. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics // J Cardiovasc Pharmacol. 1986; 8: Suppl 11: S96–9.
13. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // BMJ. May 23, 2009;338: b1665.
14. Parving H–H. Hypertension and diabetes: the scope of the problem// Blood pressure 2001; 10 (Suppl 2): 25–31.
15. Pater C, Bhatnagar D, Berrou J. P. et al. A novel approach to treatment of hypertension in diabetic patients – a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with lowdose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 – rationale and design [ISRCTN55725285] // Curr Control Trials Cardiovasc Med. 2004; 5(1): 9.
16. Rydén Lars, Standl Е. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J 2007 Suppl 9 (suppl C): 30-74
17. Schouten O., Poldermans D., Visser L. et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study // Am Heart J. 2004; Dec; 148: 6: 1047–52.
18. Sharma A M, Wagner T and Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study // J Human Hypertension 2004; 18: 669–675.
19. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease // An Update Hypertension 2001; 37: 1053– 1059.
20. Stamler J., Vaccaro O., Neaton JD, et al. for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12–year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care 1993; 16: 434–444.
21. Standards of Medical Care in Diabetes-2009. American Diabetes Association// Diabetes Care 2009: Vol.32, Suppl1, S13-60.
22. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-85
23. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes // N Engl J Med. June 12, 2008;358:2560-72.
24. U.K. Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type II diabetes: UKPDS 39 // Br Med J 1998; 317: 713-720.
25. Von Arnim T Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine// J Am Coll Cardiol 1995;25:231-8
Review
For citations:
Morozova T.E., Andrushchishina T.B. ARTERIAL HYPERTENSION IN PATIENTS WITH DIABETES MELLITUS: AN INDIVIDUALIZED CHOICE OF ANTIHYPERTENSIVE MEDICATIONS. Russian Journal of Cardiology. 2011;(2):72-77. (In Russ.)
Views:
525
Email this article 